IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

AGHEMO, ALESSIO MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.206
NA - Nord America 8.231
AS - Asia 7.672
SA - Sud America 805
AF - Africa 201
OC - Oceania 55
Continente sconosciuto - Info sul continente non disponibili 17
Totale 28.187
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.815
GB - Regno Unito 4.091
DE - Germania 2.448
CN - Cina 2.305
SG - Singapore 2.187
IT - Italia 1.234
SE - Svezia 869
RU - Federazione Russa 728
HK - Hong Kong 641
VN - Vietnam 617
BR - Brasile 597
IN - India 427
BD - Bangladesh 405
FR - Francia 395
TR - Turchia 320
CA - Canada 311
IE - Irlanda 241
UA - Ucraina 235
NL - Olanda 223
FI - Finlandia 205
KR - Corea 189
EU - Europa 114
ID - Indonesia 112
DK - Danimarca 103
JP - Giappone 97
CO - Colombia 69
ES - Italia 65
PL - Polonia 61
MX - Messico 59
CI - Costa d'Avorio 57
BE - Belgio 55
AR - Argentina 49
AU - Australia 43
GR - Grecia 43
CH - Svizzera 40
TW - Taiwan 38
RO - Romania 37
IQ - Iraq 34
UZ - Uzbekistan 32
EG - Egitto 30
IR - Iran 30
AT - Austria 29
ZA - Sudafrica 27
EC - Ecuador 25
PK - Pakistan 25
TH - Thailandia 25
PH - Filippine 23
CL - Cile 21
KH - Cambogia 21
IL - Israele 19
MA - Marocco 19
JO - Giordania 18
AE - Emirati Arabi Uniti 17
PT - Portogallo 16
SA - Arabia Saudita 16
TN - Tunisia 14
HU - Ungheria 13
VE - Venezuela 13
PE - Perù 12
LT - Lituania 11
NP - Nepal 11
NO - Norvegia 10
ET - Etiopia 9
MY - Malesia 9
PS - Palestinian Territory 9
UG - Uganda 9
BO - Bolivia 8
CR - Costa Rica 8
KZ - Kazakistan 8
NZ - Nuova Zelanda 8
CZ - Repubblica Ceca 7
AZ - Azerbaigian 6
JM - Giamaica 6
KE - Kenya 6
LV - Lettonia 6
OM - Oman 6
UY - Uruguay 6
DZ - Algeria 5
EE - Estonia 5
GT - Guatemala 5
MK - Macedonia 5
NG - Nigeria 5
RS - Serbia 5
AL - Albania 4
DO - Repubblica Dominicana 4
KG - Kirghizistan 4
MD - Moldavia 4
PA - Panama 4
PY - Paraguay 4
AO - Angola 3
BB - Barbados 3
BG - Bulgaria 3
HN - Honduras 3
LB - Libano 3
LK - Sri Lanka 3
LU - Lussemburgo 3
MQ - Martinica 3
PR - Porto Rico 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
Totale 28.234
Salva come PNG Salva come JPEG
Città #
Southend 3.730
Singapore 1.260
Ashburn 839
Chandler 670
Hong Kong 562
San Jose 473
Frankfurt am Main 454
Beijing 418
Milan 406
Seattle 397
Dallas 334
Princeton 283
Hanover 274
Wilmington 263
Fairfield 238
Dublin 234
New York 217
Ann Arbor 212
Los Angeles 211
Ho Chi Minh City 191
Council Bluffs 186
Toronto 175
Hanoi 169
Woodbridge 163
Dearborn 159
Jacksonville 157
Santa Clara 144
Nanjing 141
Lauterbourg 130
Houston 124
Bengaluru 122
Guangzhou 121
Mountain View 114
Buffalo 105
Des Moines 98
Moscow 97
Shanghai 97
Redmond 95
Boardman 91
Cambridge 88
Andover 83
Redwood City 82
Munich 76
Helsinki 74
Phoenix 72
Berlin 64
Jinan 63
Columbus 62
Hefei 62
Sakarya 61
Serra 60
Jakarta 59
São Paulo 58
Abidjan 57
Istanbul 57
Tokyo 56
Somerville 53
The Dalles 52
Bogotá 50
Rome 50
Ottawa 49
Tianjin 48
Cangzhou 46
Shenyang 46
Brussels 44
Nanchang 44
Saint Petersburg 43
Da Nang 39
Grafing 39
London 38
Changsha 36
Mumbai 34
Warsaw 34
San Diego 33
Zhengzhou 32
Athens 30
Jiaxing 29
Eitensheim 28
Shenzhen 28
Chengdu 25
Hangzhou 25
Hebei 25
Atlanta 24
Naples 24
Taipei 24
Wuhan 24
Fuzhou 23
Seoul 23
Washington 23
Brooklyn 22
Ankara 21
Haiphong 21
Nuremberg 21
Orem 21
Phnom Penh 21
Belo Horizonte 20
Johannesburg 19
Montreal 19
Pune 18
Rio de Janeiro 18
Totale 16.674
Salva come PNG Salva come JPEG
Nome #
COVID-19 and liver disease 867
Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection 706
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 619
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 437
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 402
Real life experiences in HCV management in 2018 396
Prevalence of psychiatric disorders during PEG – Interferon and Ribavirin therapy in patients with chronic hepatitis HCV-correlated 390
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients 390
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 344
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease 318
High rates of 30-day mortality in patients with cirrhosis and COVID-19 308
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 305
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 304
Indolent B-cell lymphomas treated upfront with antiviral therapy : a series of 13 patients 302
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 299
Donor/recipient match of IL28B to predict interferon response in recurrent hepatitis C 290
Liver stiffness measurement reliability and main determinants of point shear-wave elastography in patients with chronic liver disease 272
Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients 267
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegykated interferon-α2A in chronic hepatitis C : an in vitro and in vivo study 265
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 265
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir 251
S1pr2 is a key mediator of endoplasmic reticulum stress in NAFLD/ NASH pathogenesis 248
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 247
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 244
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C 242
US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C 240
Recovery after L-DOPA treatment in peg-interferon and ribavirin induced parkinsonism 232
Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method 232
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? 232
Genotype dependent pattern of peginterferon alfa-2b/ribavirin treatment failure in hepatiti sC virus infected patients with cirrhosis : a single center study of 471 naive patients 231
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 229
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 229
New horizons in hepatitis C antiviral therapy with direct-acting antivirals 229
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 228
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 225
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 224
In vivo and in vitro effect of ribavirin and interferon on erythropoiesis in patients with hepatitis C 224
High levels of factor VIII and risk of extra-hepatic portal vein obstruction 223
Allelic inhibition of displacement activity : a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 223
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C 223
Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis 222
Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients 219
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 218
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients 216
Genotype dependent pattern of Peginterferon alfa-2B/Ribavirin treatment failure in hepatitis C virus infected patients with cirrhosis : a single centre study of 471 naïve patients 214
The natural history of portal hypertension in patients with HCV related compensated cirrhosis undergoing interferon ribavirin therapy 214
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 214
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study 214
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 213
Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis 213
Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis 212
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 209
Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients : a single-centre study 208
The influence of liver fibrosis on the outcome of pegylated interferon and ribavirin anti-hac therapy : a sub-analysis of the mist study 206
The diagnostic accuracy of fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with an SVR 206
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 206
Hepatitis C virus genotypes and patterns of peginterferon alfa-2b/ribavirin treatment failure in patients with cirrhosis : a single center study of 471 naïve patients 205
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 205
Effect of the PNPLA3 I148M polymorphism on the outcome of peg-interferon plus ribavirin treatment in chronic hepatitis C 202
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 202
NPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 200
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 199
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection : a predictor of spontaneous viral clearance and sustained virological response 198
A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients 197
Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection 197
Individualized hepatocellular carcinoma risk : the challenges for designing successful chemoprevention strategies 195
In vivo and in vitro effect of ribavirin and pegylated-interferon on erythropoiesis in patients with hepatitis C 192
Increased survival of patients with HCV-related cirrhosis with a long-term response to interferon therapy 192
PNPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 192
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 192
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 191
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 189
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 187
Increased risk of hepatocellular carcinoma in HCV (+) non responder cirrhotics with high liver cell proliferation 186
Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3α hepatitis C virus infection 184
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-α2a in chronic hepatitis C: an in vitro and in vivo study 184
Renal safety in 3264 HCV patients treated with DAA-based regimens : results from a large Italian real-life study 184
Anti-TNF drugs in patients with hepatitis B or C virus infection : safety and clinical management 181
Interferoni pegilati nel trattamento dei pazienti con epatite cronica HCV : esperienze a confronti 180
Hepatorenal syndrome and novel advances in its management 180
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 177
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 176
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 175
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure 175
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 174
Evaluation of liver disease in a cohort of patients affected by thalassemia intermedia 173
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 173
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 171
Meccanismi patogenetici dell'anemia in corso di terapia antivirale in pazienti con epatite cronica HCV correlata 169
The natural history of hepatic macroregenerative nodules developing in cirrhotic patients during surveillance with ultrasound (US) 168
Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C 167
Low rates of sustained virological response to interferon and ribavirin therapy in genotype 3 infected patients with compensated cirrhosis 166
Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis 166
Liver cell proliferation and liver cancer risk in patients with hepatitis C virus-related cirrhosis under antiviral treatment 165
The natural history of macroregenerative nodules prospectively detected in cirrhotic patients under surveillance 164
Lack of alanine aminotransferase normalization in patients with an anti-hcv virological response during pegylated interferon and ribavirin therapy : a sub-analysis of the mist study 162
Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis 161
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. 160
Prospective study of dysplastic nodules in cirrhosis : correlation with CT vascular pattern, histology and development of hepatocellular carcinoma 158
Is there an 'ideal' diet for patients with NAFLD? 158
Totale 23.778
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.628
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.628
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021673 0 0 0 0 0 0 0 0 0 0 476 197
2021/20222.456 204 134 116 152 208 207 219 210 243 286 134 343
2022/20232.287 286 286 197 281 232 423 66 106 232 41 101 36
2023/20241.572 50 131 91 111 375 115 109 112 40 87 159 192
2024/20253.554 165 356 76 428 287 135 125 321 213 365 346 737
2025/20267.714 780 409 824 552 724 533 1.088 440 803 574 987 0
Totale 29.540